Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQU8B1)

Drug Name
WB-4101 Drug Info
Synonyms
WB-4101; WB4101; WB 4101; (2-(2',6'-Dimethoxy)phenoxyethylamino)methylbenzo-1,4-dioxane; (2-(2',6'-Dimethoxy)phenoxyethylamino)methylbenzodioxan; 613-67-2; CHEMBL25554; CHEBI:64098; N-(2-(2,6-Dimethoxyphenoxy)ethyl)-2,3-dihydro-1,4-benzodioxin-2-methanamine; 1,4-Benzodioxin-2-methanamine, N-(2-(2,6-dimethoxyphenoxy)ethyl)-2,3-dihydro-; N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-2-(2,6-dimethoxyphenoxy)ethanamine; 1,4-benzodioxin-2-methanamine, n-[2-(2,6-dimethoxyphenoxy)ethyl]-2,3-dihydro-; MLS000859914
Cross-matching ID
PubChem CID
5685
ChEBI ID
CHEBI:64098
CAS Number
CAS 613-67-2
TTD Drug ID
DMQU8B1

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Adrenergic receptor alpha-2C (ADRA2C)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MOXONIDINE DMGFB0E Alcohol dependence 6C40.2 Approved [6]
Dihydroergocristine DM5SQ1G Alcohol dependence 6C40.2 Approved [7]
Brimonidine DMQLT4N Ocular hypertension 9C61.01 Approved [8]
Amosulalol DML8QSZ Hypertension BA00-BA04 Approved [9]
Amezinium DM6I2WQ Hypotension BA20-BA21 Approved [10]
Propylhexedrine DMTBW2O Obesity 5B81 Approved [11]
Tetrahydrozoline DMT57WC Ocular disease 1F00.1Z Approved [12]
Rilmenidine DM13PQW Hypertension BA00-BA04 Approved [13]
Xylometazoline DMKV32D Allergic rhinitis CA08.0 Phase 4 [14]
TNX-102 DMO1234 Fibromyalgia MG30.01 Phase 3 [15]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Adrenergic receptor alpha-2A (ADRA2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lofexidine DM1WXA6 Heroin and opiate withdrawal 6C43 Approved [16]
MOXONIDINE DMGFB0E Alcohol dependence 6C40.2 Approved [6]
Connexyn DMF29Q5 Attention deficit hyperactivity disorder 6A05.Z Approved [17]
Guanfacine DMPN5IH Attention deficit hyperactivity disorder 6A05.Z Phase 4 [18]
A295 DM55GO2 Aggressive cancer 2A00-2F9Z IND submitted [19]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [20]
DSP-1200 DM4WSHG Depression 6A70-6A7Z Phase 1 [21]
MAZAPERTINE DMRHYAU N. A. N. A. Discontinued in Phase 2 [22]
NMI-870 DMU596F Sexual dysfunction HA00-HA01 Discontinued in Phase 2 [23]
SNAP-5089 DMROJEN Heart arrhythmia BC65 Terminated [24]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Adrenergic receptor alpha-1B (ADRA1B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methamphetamine DMPM4SK Anxiety Approved [25]
Propericiazine DME9JNL Psychiatric disorder 6E8Z Approved [26]
Methoxamine DMF5XQH Hypertension BA00-BA04 Approved [27]
Phendimetrazine DM6TS1N Obesity 5B81 Approved [28]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [20]
TIOSPIRONE DME5QDP N. A. N. A. Discontinued in Phase 3 [29]
Sunepitron DM6M8ZX N. A. N. A. Discontinued in Phase 3 [30]
MAZAPERTINE DMRHYAU N. A. N. A. Discontinued in Phase 2 [22]
SOU-001 DMPAEK5 Urinary incontinence MF50.2 Discontinued in Phase 2 [31]
SNAP-5089 DMROJEN Heart arrhythmia BC65 Terminated [32]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Adrenergic receptor alpha-2B (ADRA2B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MOXONIDINE DMGFB0E Alcohol dependence 6C40.2 Approved [6]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [20]
AGN-199981 DMP5Y1A Neuropathic pain 8E43.0 Phase 2 [33]
INDORAMIN DMNSJFD Hypertension BA00-BA04 Withdrawn from market [2]
MAZAPERTINE DMRHYAU N. A. N. A. Discontinued in Phase 2 [22]
SNAP-5089 DMROJEN Heart arrhythmia BC65 Terminated [24]
A-80426 DMBC3DG N. A. N. A. Terminated [34]
SK&F-104078 DMRADBU N. A. N. A. Terminated [2]
(+/-)-nantenine DM0L3GE Discovery agent N.A. Investigative [35]
R-226161 DM4BP7S Discovery agent N.A. Investigative [36]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Adrenergic receptor alpha-1D (ADRA1D)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxazosin DM9PLRH Benign prostatic hyperplasia GA90 Approved [37]
Armodafinil DMGB035 Malignant glioma 2A00.0 Approved [38]
Alfuzosin DMZVMKF Benign prostatic hyperplasia GA90 Approved [39]
Moxisylyte DMFCLYW Erectile dysfunction HA01.1 Approved [40]
Terazosin DM3JCVS Benign prostatic hyperplasia GA90 Approved [41]
Bunazosin DM4I8O7 Glaucoma/ocular hypertension 9C61 Approved [42]
Trimazosin DM1QLST Congestive heart failure BD10 Approved [43]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [20]
DL-017 DMM8GZT Hypertension BA00-BA04 Phase 1 [44]
PMID30124346-Compound-LDT8 DM5MUNG Benign prostatic hyperplasia GA90 Patented [45]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 1A receptor (HTR1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Trazodone DMK1GBJ Depression 6A70-6A7Z Approved [46]
Buspirone DMBS632 Anxiety disorder 6B00-6B0Z Approved [47]
OPC-34712 DMHG57U Major depressive disorder 6A70.3 Approved [48]
Vilazodone DM4LECQ Major depressive disorder 6A70.3 Approved [49]
Flibanserin DM70DTN Depression 6A70-6A7Z Approved [50]
Gepirone DMGX5Q0 Major depressive disorder 6A70.3 Approved [51]
TERTATOLOL DM2L3D5 Hypertension BA00-BA04 Approved [52]
Urapidil DMD59GI Hypertension BA00-BA04 Approved [53]
Treximet DMU54QB Migraine 8A80 Approved [54]
CM-2395 DMASPWR Schizophrenia 6A20 Phase 3 [55]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Adrenergic receptor alpha-1A (ADRA1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SILODOSIN DMJSBT6 Benign prostatic hyperplasia GA90 Approved [56]
NAFTOPIDIL DMQ8R4E Hypertension BA00-BA04 Approved [56]
Tamsulosin DM5QF9V Benign prostatic hyperplasia GA90 Approved [46]
Xatral DMLHOA0 Benign prostatic hyperplasia GA90 Approved [57]
Dutasteride + tamsulosin DM6P8HU Benign prostatic hyperplasia GA90 Phase 3 [54]
Besipirdine DMLVNTA Cognitive impairment 6D71 Phase 3 [58]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [20]
PMID30124346-Compound-LDT8 DM5MUNG Benign prostatic hyperplasia GA90 Patented [45]
PMID30124346-Compound-LDT66 DMJMTNL Benign prostatic hyperplasia GA90 Patented [45]
TIOSPIRONE DME5QDP N. A. N. A. Discontinued in Phase 3 [29]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Alpha-1A adrenergic receptor (ADRA1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tamsulosin DM5QF9V Benign prostatic hyperplasia GA90 Approved [59]
SILODOSIN DMJSBT6 Benign prostatic hyperplasia GA90 Approved [60]
Gabapentin DM6T924 Complex partial seizure 8A68.0 Approved [61]
Verapamil DMA7PEW Angina pectoris BA40 Approved [62]
Epinephrine DM3KJBC Acute asthma CA23 Approved [60]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [63]
Oxymetazoline DM8ZXT6 Arrhythmia BC9Z Approved [59]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [64]
Quinidine DMLPICK N. A. N. A. Approved [62]
Norepinephrine DMOUC09 Alopecia ED70 Approved [5]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By 5-hydroxytryptamine receptor 1A (HTR1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Trazodone DMK1GBJ Depression 6A70-6A7Z Approved [65]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [65]
Fluoxetine DM3PD2C Bipolar depression Approved [66]
Methamphetamine DMPM4SK Anxiety Approved [67]
Olanzapine DMPFN6Y Bipolar depression Approved [68]
Perospirone DMVHJLX Psychotic disorder 6A20-6A25 Approved [68]
Etoperidone DMR7U8F N. A. N. A. Phase 4 [65]
phorbol 12-myristate 13-acetate DMJWD62 Acute myeloid leukaemia 2A60 Phase 2 [69]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [70]
DU 125530 DM63UA9 Mood disorder 6A60-6E23 Discontinued in Phase 2 [71]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1A receptor (HTR1A) TTSQIFT 5HT1A_HUMAN Inhibitor [1]
Adrenergic receptor alpha-1A (ADRA1A) TTNGILX ADA1A_HUMAN Inhibitor [2]
Adrenergic receptor alpha-1B (ADRA1B) TTBRKXS ADA1B_HUMAN Inhibitor [2]
Adrenergic receptor alpha-1D (ADRA1D) TT34BHT ADA1D_HUMAN Inhibitor [2]
Adrenergic receptor alpha-2A (ADRA2A) TTWG9A4 ADA2A_HUMAN Inhibitor [3]
Adrenergic receptor alpha-2B (ADRA2B) TTWM4TY ADA2B_HUMAN Inhibitor [3]
Adrenergic receptor alpha-2C (ADRA2C) TT2NUT5 ADA2C_HUMAN Inhibitor [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
5-hydroxytryptamine receptor 1A (HTR1A) OT38K9MK 5HT1A_HUMAN Protein Interaction/Cellular Processes [4]
Alpha-1A adrenergic receptor (ADRA1A) OTUIWCL5 ADA1A_HUMAN Protein Interaction/Cellular Processes [5]

References

1 Synthesis of (R,S)-trans-8-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'-propenyl)amino]tetral in (trans-8-OH-PIPAT): a new 5-HT1A receptor ligand. J Med Chem. 1993 Oct 15;36(21):3161-5.
2 Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44.
3 alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401.
4 Antagonism by neuroleptics of serotonin 5-HT1A and 5-HT2 receptors of normal human brain in vitro. Eur J Pharmacol. 1987 Nov 10;143(2):279-82. doi: 10.1016/0014-2999(87)90544-9.
5 The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994 Apr;45(4):703-8.
6 Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5.
7 Effect of dihydroergocristine on blood pressure and activity at peripheral alpha-adrenoceptors in pithed rats. Eur J Pharmacol. 1984 Jan 13;97(1-2):21-7.
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 520).
9 Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
10 Pharmacology of amezinium, a novel antihypotensive drug. III. Studies on the mechanism of action. Arzneimittelforschung. 1981;31(9a):1558-65.
11 Airway compromise and delayed death following attempted central vein injection of propylhexedrine. J Emerg Med. 1994 Nov-Dec;12(6):795-7.
12 Prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline. Clin Toxicol (Phila). 2008 Feb;46(2):171-2.
13 Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. Curr Eye Res. 1996 Sep;15(9):943-50.
14 Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39.
15 Clinical pipeline report, company report or official report of Tonix Pharmaceuticals.
16 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
17 alpha2A-adrenergic receptors heterosynaptically regulate glutamatergic transmission in the bed nucleus of the stria terminalis. Neuroscience. 2009 Sep 29;163(1):339-51.
18 Scientific rationale for the use of alpha2A-adrenoceptor agonists in treating neuroinflammatory cognitive disorders. Mol Psychiatry. 2023 Apr 7:1-13.
19 Clinical pipeline report, company report or official report of Klus Pharma
20 A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
21 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
22 A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
23 Female Sexual Dysfunction: Therapeutic Options and Experimental Challenges. Cardiovasc Hematol Agents Med Chem. 2009 October; 7(4): 260-269.
24 Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8.
25 Mirtazapine treatment after conditioning with methamphetamine alters subsequent expression of place preference. Drug Alcohol Depend. 2009 Jan 1;99(1-3):231-9.
26 Interaction of neuroleptics and antidepressants with rat brain alpha 2-receptors: a possible relationship between alpha 2-receptor antagonism and antidepressant action. Biol Psychiatry. 1984 Sep;19(9):1283-91.
27 Activation of alpha1-adrenoceptors inhibits growth hormone secretion in humans. Exp Clin Endocrinol Diabetes. 2009 Oct;117(9):460-2.
28 Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
29 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996 Jan 5;39(1):143-8.
30 An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment o... J Med Chem. 2006 Jun 1;49(11):3116-35.
31 Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004 Aug;3(8):673-83.
32 Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
33 Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
34 Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71.
35 Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
36 Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-a... Bioorg Med Chem. 2007 Jun 1;15(11):3649-60.
37 The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43.
38 Mechanisms of modafinil: A review of current research. Neuropsychiatr Dis Treat. 2007 June; 3(3): 349-364.
39 Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53.
40 Pharmacokinetics of moxisylyte in healthy volunteers after intracavernous injection of increasing doses. Eur J Clin Pharmacol. 1996;49(5):411-5.
41 Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis. 2002;5(2):88-95.
42 Bunazosin, a selective alpha1-adrenoceptor antagonist, as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. Cardiovasc Drug Rev. 2005 Spring;23(1):43-56.
43 The hypotensive effect of trimazosin is not caused solely by alpha 1-adrenoceptor blockade. J Cardiovasc Pharmacol. 1984 Jan-Feb;6(1):142-50.
44 Antihypertensive action and blockade of alpha1-adrenoceptors by DL-017, a quinazoline derivative. J Cardiovasc Pharmacol. 2001 Dec;38(6):893-9.
45 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
46 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
47 Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
48 Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
49 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
50 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
51 Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
52 Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
53 Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
54 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
55 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
56 Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
57 Pharma & Vaccines. Product Development Pipeline. April 29 2009.
58 Alpha-Adrenergic activity and cardiovascular effects of besipirdine HCl (HP 749) and metabolite P7480 in vitro and in the conscious rat and dog. J Pharmacol Exp Ther. 1997 Apr;281(1):337-46.
59 Cell membrane chromatography competitive binding analysis for characterization of 1A adrenoreceptor binding interactions. Anal Bioanal Chem. 2011 Jul;400(10):3625-33. doi: 10.1007/s00216-011-5026-z. Epub 2011 May 5.
60 Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors. Cardiovasc Res. 2004 Sep 1;63(4):662-72. doi: 10.1016/j.cardiores.2004.05.014.
61 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
62 Effects of quinidine and verapamil on human cardiovascular alpha1-adrenoceptors. Circulation. 1998 Apr 7;97(13):1227-30. doi: 10.1161/01.cir.97.13.1227.
63 Adipogenic Effects and Gene Expression Profiling of Firemaster? 550 Components in Human Primary Preadipocytes. Environ Health Perspect. 2017 Sep 14;125(9):097013. doi: 10.1289/EHP1318.
64 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
65 Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. doi: 10.1007/BF02244985.
66 Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J. 2006 Jan-Feb;6(1):27-33. doi: 10.1038/sj.tpj.6500340.
67 Serotonin 1A receptor gene is associated with Japanese methamphetamine-induced psychosis patients. Neuropharmacology. 2010 Feb;58(2):452-6. doi: 10.1016/j.neuropharm.2009.09.006. Epub 2009 Sep 10.
68 Serotonin-1A receptor gene polymorphism and the ability of antipsychotic drugs to improve attention in schizophrenia. Adv Ther. 2010 May;27(5):307-13. doi: 10.1007/s12325-010-0035-4. Epub 2010 Jun 8.
69 Mechanisms of regulation of agonist efficacy at the 5-HT(1A) receptor by phospholipid-derived signaling components. J Pharmacol Exp Ther. 2001 Jun;297(3):1025-35.
70 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
71 5-Hydroxytryptamine1A receptor occupancy by novel full antagonist 2-[4-[4-(7-chloro-2,3-dihydro-1,4-benzdioxyn-5-yl)-1-piperazinyl]butyl]-1,2-benzisothiazol-3-(2H)-one-1,1-dioxide: a[11C][O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide trihydrochloride (WAY-100635) positron emission tomography study in humans. J Pharmacol Exp Ther. 2002 Jun;301(3):1144-50.